Richard Adcock Net Worth

The estimated Net Worth of Richard Adcock is at least $4.87 Milion dollars as of 5 February 2021. Mr. Adcock owns over 150,000 units of NantKwest Inc stock worth over $4,873,500 and over the last 4 years he sold NK stock worth over $0. In addition, he makes $0 as Chief Executive Officer at NantKwest Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Adcock NK stock SEC Form 4 insiders trading

Richard has made over 1 trades of the NantKwest Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 150,000 units of NK stock worth $4,873,500 on 5 February 2021.

The largest trade he's ever made was exercising 150,000 units of NantKwest Inc stock on 5 February 2021 worth over $4,873,500. On average, Richard trades about 150,000 units every 0 days since 2021. As of 5 February 2021 he still owns at least 150,000 units of NantKwest Inc stock.

You can see the complete history of Mr. Adcock stock trades at the bottom of the page.

Richard Adcock biography

Richard Adcock serves as Chief Executive Officer of the Company. Mr. Adcock was most recently CEO of Verity Health Systems, a California-based nonprofit healthcare system that he steered through a successful restructuring event. Prior to joining Verity Health, Adcock served as Executive Vice President and Chief Innovation Officer for Sanford Health, the largest rural nonprofit healthcare system in the U.S. with more than 382 locations and 28,000 employees. While at Sanford, he was responsible for leading the healthcare company's growth and innovation, in addition to direct operational oversight of related entities including Sanford Research, Sanford Health Plan, Sanford Foundation and Sanford Frontiers. During his time at Sanford he learned firsthand how essential it is to keep the patient at the center of all healthcare decisions, this was even more important as Sanford Health brought forth many new exciting treatments, therapies and medical devices from their own research efforts. Earlier in his career, Adcock was director of engineering and a Six Sigma Master Black Belt for GE Medical Systems. He began his career in the medical field as co-owner and vice president of research and development at medical equipment supplier Micro Medical Systems.

How old is Richard Adcock?

Richard Adcock is 52, he's been the Chief Executive Officer of NantKwest Inc since 2020. There are 6 older and 1 younger executives at NantKwest Inc. The oldest executive at NantKwest Inc is Frederick Driscoll, 69, who is the Lead Independent Director.

What's Richard Adcock's mailing address?

Richard's mailing address filed with the SEC is C/O NANTKWEST, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121.

Insiders trading at NantKwest Inc

Over the last 9 years, insiders at NantKwest Inc have traded over $20,345,739 worth of NantKwest Inc stock and bought 4,163,265 units worth $55,365,252 . The most active insiders traders include Patrick Cambridge Equities,..., Steve Gorlin a Barry J. Simon. On average, NantKwest Inc executives and independent directors trade stock every 33 days with the average trade being worth of $5,362,832. The most recent stock trade was executed by Richard Adcock on 5 February 2021, trading 150,000 units of NK stock currently worth $4,873,500.

What does NantKwest Inc do?

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.

Complete history of Mr. Adcock stock trades at NantKwest Inc

NantKwest Inc executives and stock owners

NantKwest Inc executives and other stock owners filed with the SEC include:

• Barry Simon,
  President, Chief Administrative Officer, Director
• Sonja Nelson,
  Chief Financial Officer
• Cheryl Cohen,
  Director
• Patrick Soon-Shiong,
  Executive Chairman of the Board
• Frederick Driscoll,
  Lead Independent Director
• John Thomas,
  Independent Director
• Michael Blaszyk,
  Independent Director
• Richard Adcock,
  Chief Executive Officer
• John T Jr Potts,
  Director
• Richard Kusserow,
  Director
• Angela Wilson,
  Chief Financial Officer
• Steve Gorlin,
  Director
• Richard J. Tajak,
  Chief Financial Officer
• Patrickmp 13 Ventures, Llc ...,
  Chairman and CEO
• Patrick Chan Soon Shiong Fa...,
  Chairman and CEO